{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:16:54Z","timestamp":1790662614710,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T00:00:00Z","timestamp":1368576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10157-013-0815-7","type":"journal-article","created":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T23:45:39Z","timestamp":1368488739000},"page":"135-143","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy"],"prefix":"10.1007","volume":"18","author":[{"given":"Masafumi","family":"Fukagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanand","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,15]]},"reference":[{"key":"815_CR1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","volume":"15","author":"AP Guerin","year":"2000","unstructured":"Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"815_CR2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478\u201383.","journal-title":"N Engl J Med"},{"key":"815_CR3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","volume":"67","author":"EW Young","year":"2005","unstructured":"Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179\u201387.","journal-title":"Kidney Int"},{"key":"815_CR4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11255-005-0083-x","volume":"38","author":"M Wei","year":"2006","unstructured":"Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K\/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol. 2006;38:739\u201343.","journal-title":"Int Urol Nephrol"},{"key":"815_CR5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","volume":"55","author":"K Uhlig","year":"2010","unstructured":"Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010;55:773\u201399.","journal-title":"Am J Kidney Dis"},{"key":"815_CR6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1681\/ASN.2007050622","volume":"19","author":"GM London","year":"2008","unstructured":"London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19:1827\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"815_CR7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.23","volume":"77","author":"GA Block","year":"2010","unstructured":"Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77:897\u2013903.","journal-title":"Kidney Int"},{"key":"815_CR8","unstructured":"Novartis Clinical Trial Results Database. A 12-week, open label, multicentre, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer-HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis. Accessed 25 May 2012."},{"key":"815_CR9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1797.2011.01509.x","volume":"16","author":"JB Chen","year":"2011","unstructured":"Chen JB, Chiang SS, Chen HC, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomised, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16:743\u201350.","journal-title":"Nephrology (Carlton)"},{"key":"815_CR10","first-page":"647A","volume":"21","author":"JB Chen","year":"2010","unstructured":"Chen JB, Chiang SS, Chen HC, et al. SBR759 is more effective than sevelamer hydrochloride in sustaining serum phosphate reduction in hemodialysis. J Am Soc Nephrol. 2010;21:647A.","journal-title":"J Am Soc Nephrol"},{"key":"815_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","volume":"12","author":"T Shigematsu","year":"2008","unstructured":"Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2008;12:55\u201361.","journal-title":"Ther Apher Dial"},{"key":"815_CR12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","volume":"15","author":"LA Stevens","year":"2004","unstructured":"Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"815_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","volume":"44","author":"EW Young","year":"2004","unstructured":"Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"815_CR14","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.2215\/CJN.05880809","volume":"5","author":"P Raggi","year":"2010","unstructured":"Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010;5(Suppl 1):S31\u201340.","journal-title":"Clin J Am Soc Nephrol"},{"key":"815_CR15","first-page":"647A","volume":"21","author":"T Akiba","year":"2010","unstructured":"Akiba T, Chen JB, Chen HC, et al. SBR759 is well-tolerated with good gastrointestinal tolerability profile compared to Sevelamer Hydrochloride. J Am Soc Nephrol. 2010;21:647A.","journal-title":"J Am Soc Nephrol"},{"key":"815_CR16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000320733","volume":"32","author":"T Nakanishi","year":"2010","unstructured":"Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32:439\u201346.","journal-title":"Am J Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-013-0815-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-013-0815-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-013-0815-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:44:38Z","timestamp":1559112278000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-013-0815-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1007\/s10157-013-0815-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,15]]}}}